EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches

Lili Zhou, Wei Cheng, Qingqing Luo, Chunhong Huang, Li Yu

International Immunopharmacology · 2025-08 · 161 · 115012

DOI: 10.1016/j.intimp.2025.115012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-08. Verfasst von Lili Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematolo…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Tumor Microenvironment, Epigenesis, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation, Innovative Research Group Project of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma, despite significant advancements in therapy, a substantial proportion of patients will relapse or exhibit refractory disease. DLBCL exhibits complex interactions between tumor cells and their microenvironment, significantly influenced by epigenetic dysregulation. Recent advances in genomics, transcriptomics and single-cell analyses have unveiled how epigenetic alterations - including DNA methylation, histone modifications, and RNA editing - dynamically regulate immune evasion and tumor progression. These findings have paved the way for novel therapies aimed at reversing epigenetic dysregulation and restoring immune surveillance. We evaluate promising epigenetic-targeting strategies in clinical development and propose key research directions to accelerate their translation into effective combination therapies. By linking fundamental research to clinical applications, this review aims to provide actionable insights for advancing precision medicine in DLBCL, with the ultimate goal of improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseTumor MicroenvironmentEpigenesis, GeneticHumansAnimalsDNA MethylationMolecular Targeted TherapyPrecision MedicineCellular Reprogramming

Stichwörter der Autor:innen

Diffuse large B-cell lymphomaEpigenetic reprogrammingTumor microenvironment

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052), Nanchang, Jiangxi, China.
  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052), Nanchang, Jiangxi, China. Electronic ad…

Förderung

  • National Natural Science Foundation of China
  • Jiangxi Provincial Natural Science Foundation
  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province

Zitieren

APA

Zhou, L., Cheng, W., Luo, Q., Huang, C., & Yu, L. (2025). Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches. International Immunopharmacology, 161, 115012. https://doi.org/10.1016/j.intimp.2025.115012

Vancouver

Zhou L, Cheng W, Luo Q, Huang C, Yu L. Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches. International Immunopharmacology. 2025;161:115012. doi:10.1016/j.intimp.2025.115012

BibTeX
@article{Zhou2025,
  author = {Zhou, Lili and Cheng, Wei and Luo, Qingqing and Huang, Chunhong and Yu, Li},
  title = {Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {161},
  pages = {115012},
  doi = {10.1016/j.intimp.2025.115012}
}
Kostenlos starten →